中证报中证网讯(王珞)12月9日，国家药品监督管理局(NMPA)官网发布公告，上海医药（601607）集团 股份有限公司(以下简称"上海医药")全资子公司上海上药信谊药厂有限公司申报的1类创新药苹果酸司 妥吉仑片(研发代号：SPH3127，商品名：信妥安，以下简称"司妥吉仑")获批上市，适用于原发性高血 压治疗。 作为沪港两地上市的大型医药产业集团，上海医药始终将研发创新置于战略核心，2024年研发总投入达 28.18亿元，投入强度位列行业领先水平；截至2025年三季度末，上海医药提交临床试验申请获得受理 及进入后续临床试验阶段的新药管线共计57项，含创新药管线45项，已构建起全周期、阶梯式研发梯 队。其中，拟用于治疗视神经脊髓炎的创新型CD20注射剂B001，拟用于治疗轻、中度脊髓型颈椎病的 中药1类新药参芪麝蓉丸均已完成III期临床试验全部受试者入组；拟用于治疗肌萎缩侧索硬化症(渐冻 症)的中药1类新药SRD4610，拟用于治疗急性缺血性脑卒中的化药1类新药SHPL-49，近期也都已开展 III期临床试验。司妥吉仑的获批，正是上海医药长期布局创新药管线的阶段性收获。 同时，上海医药充分发挥"链主"企业作用 ...

格隆汇12月11日｜中邮证券研报指出，上海医药商业板块稳健增长，Q3减值影响利润，看好创新业务 驱动成长。公司医药商业业务继续保持增长韧性，优势区域增长态势强劲，器械大健康业务表现亮眼， 新零售战略调整成效显现，CSO业务规模再创新高，创新药产品结构持续优化，供应链服务面向专业化 与价值链高端延伸。2025Q1-3公司创新药业务实现销售收入407亿元，同比增长超过25%；进口总代业 务实现销售收入276亿元，同比增长超过14%；器械大健康业务实现销售收入339.88亿元，同比增长超 过4%。截至2025年9月30日，公司提交临床试验申请获得受理及进入后续临床试验阶段的新药管线共计 57项，包括创新药管线45项。维持"买入"评级。 ...

中证港股通央企红利指数（931233.CSI），从港股通范围内，选取中央企业实际控制的分红水平稳定且 股息率较高的50只上市公司股票进行打包；截至12月10日，该指数近1年股息率是6.75%，高于同期10 年期国债收益率4.88%，港股央企红利ETF（513910）是跟踪该指数规模最大的投资标的。 恒生中国内地企业高股息率指数（HSMCHYI.HI），筛选打包在港上市，内地公司中的高股息股票；截 至12月10日，该指数近1年股息率是6.21%，高于同期10年期国债收益率4.34%，恒生红利ETF （159726）是跟踪该指数的唯一ETF。 注：除净日，就是一只股票开始"剔除"即将派发的股息（红利）的日期。从这一天起，买入该股票的投 资者，将无法享受到本次派发的股息。 非标普港股通低波红利港币指数（SPAHLVHP.SPI）筛选打包在港上市的50只高股息低波动股票，港股 通红利低波ETF（159118）是跟踪该指数综合费率最低的一只ETF。 上海医药（601607）：每股0.13215港元；除净日：2025-12-29，派息日期：2026-02-06；恒生行业：药 品分销；非中证港股通央企红利指数（931233 ...

证券研究报告：医药生物 | 公司点评报告 发布时间：2025-12-11 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 17.80 | | --- | --- | | 总股本/流通股本（亿股）37.08 | / 27.89 | | 总市值/流通市值（亿元）660 | / 496 | | 52 周内最高/最低价 | 21.97 / 17.47 | | 资产负债率(%) | 62.1% | | 市盈率 | 14.47 | | 第一大股东 | HKSCC NOMINEES | | LIMITED | | 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:龙永茂 SAC 登记编号:S1340523110002 Email:longyongmao@cnpsec.com 上海医药(601607) 减值影响利润，看好创新业务驱动成长 l 商业板块稳健增长，Q3 减值影响利润 公司发布 2025 年三季报：2025Q1-3 公司实现营业收入 2150.72 亿元（+2.60%），其中医药工业实现销售收 ...

恒生中国内地企业高股息率指数（HSMCHYI.HI），筛选打包在港上市，内地公司中的高股息股票； 截至12月10日，该指数近1年股息率是6.21%，高于同期10年期国债收益率4.34%，恒生红利ETF （159726）是跟踪该指数的唯一ETF。 中证港股通央企红利指数（931233.CSI），从港股通范围内，选取中央企业实际控制的分红水平稳定且 股息率较高的50只上市公司股票进行打包；截至12月10日，该指数近1年股息率是6.75%，高于同期10 年期国债收益率4.88%，港股央企红利ETF（513910）是跟踪该指数规模最大的投资标的。 非标普港股通低波红利港币指数（SPAHLVHP.SPI）筛选打包在港上市的50只高股息低波动股票，港股 通红利低波ETF（159118）是跟踪该指数综合费率最低的一只ETF。 上海医药：每股0.13215港元；除净日：2025-12-29，派息日期：2026-02-06；恒生行业：药品分销；非 中证港股通央企红利指数（931233.CSI）的成分股，非恒生中国内地企业高股息率指数 （HSMCHYI.HI）的成分股，非标普港股通低波红利港币指数（SPAHLVHP.SPI）的成 ...

北京商报讯（记者 王寅浩 宋雨盈）12月10日，上海医药发布公告称，公司下属上海上药信谊药厂有限 公司收到国家药品监督管理局下发的《药品注册证书》（药品批准文号：国药准字 H20250067），由其 提交的苹果酸司妥吉仑片（SPH3127片）的药品上市许可申请获国家药监局批准。 公告显示，苹果酸司妥吉仑片是新一代口服非肽类小分子肾素抑制剂，通过对肾素的直接抑制，拮抗由 肾素-血管紧张素-醛固酮系统（RAAS）过度激活造成的血压上升，适用于原发性高血压的治疗。 ...

Group 1 - Jicheng Electronics won a total of 15 bids from the State Grid Corporation, with a total bid amount of approximately 215 million yuan, accounting for 8.27% of the company's projected revenue for 2024 [2] - Jianmin Group's chemical generic drug, Ambrutoro Oral Solution, has been approved for market launch by the National Medical Products Administration, aimed at treating cough and wheezing caused by chronic bronchitis and emphysema [3] - Taiji Industry's subsidiary plans to transfer accounts receivable not exceeding 85 million USD to optimize cash flow, with an expected service fee of approximately 285,000 USD [4] Group 2 - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [5] - Ruili Kemi received a development notification from a well-known domestic flying car company to supply core components [6] - Ding Tong Technology announced that several executives plan to reduce their holdings by a total of no more than 45,300 shares, representing about 0.032% of the total share capital [7][8] Group 3 - Ninghu Expressway's subsidiary plans to invest no more than 9.033 billion yuan in the construction of the Nanyang Yangtze River Bridge South Connection Project [10] - Wuliangye announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 25.78 yuan per 10 shares, totaling approximately 10 billion yuan [12] - Beixin Road and Bridge's subsidiary won a bid for a project worth 180 million yuan [14] Group 4 - Minhe Livestock reported a 7.75% month-on-month increase in sales revenue from commodity chick sales in November [15] - Xuelong Group plans to invest 100 million yuan to establish a wholly-owned subsidiary for vertical integration in the aluminum and magnesium technology sector [16] - Shengnong Development reported a 15.77% year-on-year increase in sales revenue in November, with significant growth in both poultry and processed meat products [17] Group 5 - Xingyu Co., Ltd. plans to repurchase shares worth 200 million to 300 million yuan for employee stock ownership plans [18] - Quan Chai Power intends to use 50 million yuan of idle funds to purchase structured deposit products [19] - Shibei High-tech appointed Zhao Junhong as the new deputy general manager [20] Group 6 - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, expanding its anti-infection product line [21] - Xiaoming Co. reported a 49.73% year-on-year decline in chicken product sales revenue in November [22] - Baiao Chemical adjusted its share repurchase price ceiling to no more than 48.95 yuan per share [23] Group 7 - Hefei China reported a 26.02% year-on-year decline in consolidated revenue for the first 11 months [24] - Laimei Pharmaceutical's subsidiary received medical device registration certificates for two endoscope products [25][26] - Xiantan Co. reported an 11.63% year-on-year increase in chicken product sales revenue in November [27] Group 8 - Qilin Security received government subsidies totaling 5.4014 million yuan [28] - Blue Sky Gas's controlling shareholder's 30.9134 million shares were judicially frozen, accounting for 4.33% of the total share capital [29] - Tieke Railway signed a contract for high-speed railway fasteners worth 654 million yuan, accounting for 41.08% of the company's projected revenue for 2024 [30] Group 9 - David Medical's electric surgical table received a medical device registration certificate [31] - Zhendong Pharmaceutical's affiliate's core product new drug application was accepted by the CDE [32] - Shanghai Pharmaceutical's apple acid sitagliptin tablet application for market approval was granted by the National Medical Products Administration [33] Group 10 - Nanjiao Food reported a 1.14% year-on-year increase in consolidated revenue for November [34]

上海医药（601607）(02607)发布公告，近日，公司下属上海上药信谊药厂有限公司(上药信谊)收到国家 药监局下发的《药品注册证书》(药品批准文号：国药准字H20250067)，由其提交的苹果酸司妥吉仑片 (即SPH3127片)的药品上市许可申请获国家药监局批准。 苹果酸司妥吉仑片是新一代口服非肽类小分子肾素抑制剂，通过对肾素的直接抑制，拮抗由肾素-血管 紧张素-醛固酮系统(RAAS)过度激活造成的血压上升，适用于原发性高血压的治疗。体外和体内药效学 研究均表明，苹果酸司妥吉仑片比同靶点药物具有更强的肾素活性抑制作用，并且在高血压、慢性肾病 和炎症性肠病模型中证实了其药效学特征。已完成的临床研究表明，苹果酸司妥吉仑片总体安全性良 好，在高血压患者人群中显示出了明确的降压疗效，能够进一步满足原发性高血压患者的临床需求，为 原发性高血压患者提供一种新的治疗选择。截止目前，苹果酸司妥吉仑片相关项目累计已投入研发费用 约2.96亿元。 本次苹果酸司妥吉仑片(即SPH3127片)获得上市许可标志着上药信谊具备在国内市场生产和销售该药品 的资格。同时，公司高度重视药品研发，并严格控制药品研发、制造及销售环节的质量及安 ...

Core Insights - Shanghai Pharmaceuticals (02607) announced that its subsidiary, Shanghai Shenyin Pharmaceutical Factory, received the drug registration certificate for SPH3127 (also known as Apixaban) from the National Medical Products Administration [1][2] - SPH3127 is a new generation oral non-peptide small molecule renin inhibitor, designed to treat primary hypertension by directly inhibiting renin, counteracting the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - Clinical studies have shown that SPH3127 has a good overall safety profile and significant antihypertensive efficacy in patients with primary hypertension, providing a new treatment option for this patient group [1] Company Developments - The approval of SPH3127 marks Shanghai Shenyin's qualification to produce and sell the drug in the domestic market [2] - The company emphasizes the importance of drug research and development, maintaining strict quality and safety controls throughout the drug development, manufacturing, and sales processes [2] - The total research and development investment for SPH3127 has reached approximately 296 million yuan [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) has received approval from the National Medical Products Administration for its new drug, SPH3127 tablets, which are a new generation of oral non-peptide small molecule renin inhibitors for the treatment of primary hypertension [1] Company Summary - The drug SPH3127 is designed to directly inhibit renin, counteracting the increase in blood pressure caused by the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - The approval of SPH3127 represents a significant advancement in the company's product offerings in the hypertension treatment market [1] Industry Summary - The approval of new hypertension treatments like SPH3127 reflects ongoing innovation in the pharmaceutical industry, particularly in the development of targeted therapies for cardiovascular conditions [1] - The introduction of non-peptide small molecule inhibitors may enhance treatment options for patients with primary hypertension, potentially impacting market dynamics [1]